ACADIA Pharmaceuticals Inc (STU:DR6)
€ 16.37 1.79 (12.28%) Market Cap: 2.72 Bil Enterprise Value: 2.24 Bil PE Ratio: 22.05 PB Ratio: 4.96 GF Score: 73/100

ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 05:00PM GMT
Release Date Price: €27 (-0.74%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is ACADIA Pharmaceuticals. And speaking on behalf of the company, we're pleased to have CEO, Steve Davis. Steve?

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - President, CEO & Director

Great. Thanks much, Tess, and thanks to each of you for coming out today. I need to start with the obligatory disclaimer regarding forward-looking statements. The business of drug discovery development and commercialization has a lot of inherent risks. Please see our most recent SEC filings for a description of those risks as they relate to our business.

Our business rests on 3 pillars. We have 2 successful commercial franchises driving record revenues, 3 late-stage assets with a strong early-stage pipeline fueling future growth. And we're a cash flow positive company, which further enables us to pursue that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot